• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Riociguat(625115-55-1)
Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-
1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)
1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

Lupin launches Zileuton extended-release tablets

expresspharmaAugust 12, 2020

Tag: lupin , Zileuton , FDA

Lupin announced the launch of Zileuton extended-release tablets, 600 mg, having received an approval from the United States Food and Drug Administration (US FDA) earlier. The product would be manufactured at Lupin’s Nagpur facility, India.

Zileuton extended-release tablets, 600 mg, is the generic equivalent of Zyflo CR extended-release tablets, 600 mg, of Chiesi USA, and is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Zileuton extended-release tablets had annual sales of approximately $40 million in the US (IQVIA MAT June 2020).


Previous:Daewoong Pharma gets CDSCO nod to test anti-parasite drug for COVID-19

Next:Roche gets US FDA approval for Evrysdi to treat spinal muscular atrophy

Related News

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Innovent Biologics announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ® .

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Macrogen Consortium win tender for National Bio Big Data Project

PRNewswireDecember 23, 2024

Lupin launches Zileuton extended-release tablets | Pharmasources.com

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

SCG Cell Therapy Pte Ltd (SCG),announced the signing of a Memorandum of Understanding (MoU) with A*STAR BTI and NATi to advance RNA-based therapeutics manufacturing process development and clinical translation.

You may like
More>>

Hemisuccinate /Sodium (FDA/DMF)

Hemisuccinate /Sodium (FDA/DMF)
Dobutamine HCL (FDA)

Dobutamine HCL (FDA)
Fluorfenicol( FDA)

Fluorfenicol( FDA)
Sirolimus (FDA)

Sirolimus (FDA)
Semaglutide(FDA)

Semaglutide(FDA)
9,9-Bis(4-aminophenyl) Fluorene (FDA)

9,9-Bis(4-aminophenyl) Fluorene (FDA)
Deltamine (FDA)

Deltamine (FDA)
Thiophosphoramide (FDA)

Thiophosphoramide (FDA)
Tobramycin base( FDA)

Tobramycin base( FDA)
Simvastatin (FDA)

Simvastatin (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service